摘要
目的:探讨利妥昔单抗联合甲泼尼龙在脊髓炎患者中的临床疗效及对趋化因子和炎症因子的影响。方法:选取164例脊髓炎患者为研究对象,按照治疗方式不同将患者分为对照组和观察组,每组各82例。对照组仅接受利妥昔单抗治疗;观察组在此基础上联合使用甲泼尼龙治疗,治疗后对患者治疗效果进行评估,比较两组生存质量、趋化因子[嗜酸性粒细胞趋化因子1(Eot1);嗜酸性粒细胞趋化因子2(Eot2);嗜酸性粒细胞趋化因子3(Eot3)]水平及炎症因子[白细胞介素6(IL-6)、IL-8、肿瘤坏死因子α(TNF-α)]水平。结果:治疗后,两组生存质量各维度评分均升高(P<0.05),且观察组高于对照组(P<0.05)。治疗后,两组Eot1、Eot2、Eot3水平均降低(P<0.05),且观察组低于对照组(P<0.05);两组IL-6、IL-8、TNF-α水平均降低(P<0.05),且观察组低于对照组(P<0.05)。结论:利妥昔单抗联合甲泼尼龙在脊髓炎患者中应用具有显著疗效,可明显改善患者趋化因子水平,调节炎症因子水平,改善患者的生存质量,获得良好的治疗预后,值得推广应用。
Objective:To investigate the clinical effect of rituximab combined with methylprednisolone in patients with myelitis and its influence on chemokines and inflammatory factors.Methods:A total of 164 patients with myelitis were divided into a control group and an observation group according to the different treatment methods,with 82 patients in each group.The control group received only rituximab,while the observation group received rituximab combined with methylprednisolone.After the treatment,the patient's effect was evaluated,and the quality of life,the level of cytokines(Eot1,Eot2,Eot3)and the level of inflammatory factors[interleukin-6(IL-6),IL-8,tumor necrosis factor-α(TNF-α)]were compared between the two groups.Results:After treatment,the scores of various dimensions of quality of life in both groups increased(P<0.05),and the observation group was higher than the control group(P<0.05).The levels of Eot1,Eot2,and Eot3 decreased in both groups,and the observation group was lower than the control group(P<0.05).The levels of IL-6,IL-8,and TNF-αdecreased in both groups,and the observation group was lower than the control group(P<0.05).Conclusion:The application of rituximab combined with methylprednisolone has a significant effect in patients with myelitis.It can significantly improve the level of cytokines in patients,adjust the level of inflammatory factors,improve the quality of life of patients,and obtain a good prognosis.It is worth of promote applications.
作者
熊益
郭灿收
XIONG Yi;GUO Can-shou(Department of Neurology,the Sixth Hospital of Wuhan,Affiliated Hospital of Jianghan University,Wuhan 430000,Hubei,China)
出处
《川北医学院学报》
CAS
2024年第10期1352-1355,共4页
Journal of North Sichuan Medical College
基金
湖北省武汉市卫生健康委员会青年项目(WX21Q47)。
关键词
利妥昔单抗
甲泼尼龙
脊髓炎患者
趋化因子
炎症因子
生存质量
Rituximab
Methylprednisolone
Patients with myelitis
Cytokines
Inflammatory factors
Quality of life
